Unoprostone ophthalmic Pregnancy and Breastfeeding Warnings
Brand names: Rescula
Unoprostone ophthalmic Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Animal studies have shown an increase in the incidence of miscarriages, an increase in the incidence of premature delivery, a decrease in live birth index, and a decrease in weight at birth. There are no adequate and well-controlled studies in pregnant women.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Unoprostone ophthalmic Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- (2001) "Product Information. Rescula (unoprostone ophthalmic)." Ciba Vision Ophthalmics
References for breastfeeding information
- (2001) "Product Information. Rescula (unoprostone ophthalmic)." Ciba Vision Ophthalmics
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.